CytomX Therapeutics Announces New Employment Inducement Grants
20 Juli 2023 - 3:00PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated oncology therapeutics, today announced that
on July 19, 2023, the Company granted its recently appointed Senior
Vice President, Chief Medical Officer, Yu-Waye (Wayne) Chu, M.D.,
an option to purchase 375,000 shares of the Company’s common stock
and also granted an additional new employee options to purchase
2,500 shares of the Company’s common stock, at an exercise price
per share equal to $1.82, which was the closing trading price on
July 19, 2023, the date of the grants.
The stock options were granted pursuant to the
Company’s 2019 Employment Inducement Incentive Plan, which was
approved by the Company’s board of directors in August 2020 under
Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to
induce new employees to enter into employment with the Company.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company focused
on developing novel conditionally activated biologics localized to
the tumor microenvironment. By pioneering a novel class of
conditionally activated biologics, powered by its Probody®
technology platform, CytomX’s goal is to transcend the limits of
current cancer treatments. CytomX’s robust and differentiated
pipeline comprises therapeutic candidates across multiple treatment
modalities including antibody-drug conjugates (“ADCs”), T-cell
engaging bispecific antibodies (“TCBs”), and immune modulators such
as cytokines and checkpoint inhibitors (“CPIs”). CX-2029 is an
investigational conditionally activated antibody-drug conjugate
(ADC) directed toward CD71. CytomX’s clinical pipeline also
includes cancer immunotherapeutic candidates against validated
targets such as the CTLA-4-targeting Probody therapeutic
BMS-986288, partnered with Bristol Myers Squibb, as well as
CX-904, a conditionally activated T-cell-engaging bispecific
antibody targeting the epidermal growth factor receptor (EGFR) on
tumor cells and the CD3 receptor on T cells, which is partnered
with Amgen. In addition, CytomX has a diverse preclinical portfolio
of wholly-owned assets including CX-801, an interferon alpha-2b
Probody cytokine that has broad potential applicability in
traditionally immuno-oncology sensitive as well as insensitive
(cold) tumors and CX-2051, a conditionally activated ADC directed
toward EpCAM, with potential applicability across multiple
EpCAM-expressing epithelial cancers. CytomX has also established
strategic collaborations with multiple leaders in oncology,
including Amgen, Astellas, Bristol Myers Squibb, Regeneron and
Moderna. For more information about CytomX and how it is working to
make conditionally activated treatments the new standard-of-care in
the fight against cancer,
visit www.cytomx.com and follow us
on LinkedIn and Twitter.
Probody is a U.S. registered trademark of CytomX
Therapeutics, Inc.
CytomX Contact:Chris OgdenSVP,
Finance and Accounting cogden@cytomx.com(317) 767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024